Adagene Raises $50M in Series C Funding

Adagene Inc., a Suzhou, China-based antibody discovery and development company, raised $50m in Series C financing.

The round was led by Sequoia China, with participation from New World TMT, AVIC Trust, King Star Capital, Gopher Asset Management as well as other investors.

The funds will be used to advance novel antibody therapeutics into human trials across the globe.

Led by co-founder and CEO Dr. Peter Luo, Adagene has developed the Dynamic Precision Library [DPL] platform which is leveraged to discover highly differentiated portfolio of agonist and antagonist therapeutic antibodies, now advanced into clinical trials.



Join the discussion